TB Alliance and Lupin partner to manufacture anti-TB drug pretomanid
The TB Alliance has granted Lupin a non-exclusive license to manufacture the anti-TB drug pretomanid as part of the three-drug BPaL regimen. Lupin intends to commercialise the anti-tuberculosis (TB) medicine in approximately 140 countries and territories
Anti-TB Drug Pretomanid | 07/09/2021 | By Darshana | 358
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy